IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i2d10.1007_s40264-020-01005-3.html
   My bibliography  Save this article

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)

Author

Listed:
  • Priya Bahri

    (European Medicines Agency)

  • Daniel R. Morales

    (University of Dundee
    European Medicines Agency, Pharmacovigilance Risk Assessment Committee)

  • Adrien Inoubli

    (Agence Nationale de Sécurité du Médicament et des Produits de Santé
    European Medicines Agency, Pharmacovigilance Risk Assessment Committee)

  • Jean-Michel Dogné

    (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten-Agence Fédérale des Médicaments et des Produits de Santé
    European Medicines Agency, Pharmacovigilance Risk Assessment Committee)

  • Sabine M. J. M. Straus

    (College ter Beoordeling van Geneesmiddelen
    European Medicines Agency, Pharmacovigilance Risk Assessment Committee)

Abstract

Introduction Understanding the impact of regulatory actions for medicines and enablers/barriers for positive health outcomes is fundamental to effective risk minimisation measures (RMM). Therefore, the Impact Strategy of the European Union (EU) Pharmacovigilance Risk Assessment Committee (PRAC) includes engagement with patient communities and healthcare professional (HCP) bodies regarding RMM. However, there is uncertainty on how best to obtain stakeholder input. Objectives The objectives of this study were to (1) analyse stakeholder input at a public hearing and dedicated meeting for the 2017–18 EU procedure on valproate teratogenicity and (2) draw proposals for enhancing PRAC engagement. Methods For the content analysis, the novel ‘Analysing Stakeholder Safety Engagement Tool’ (ASSET) was developed with 21 themes in six domains (appropriateness, access, audience, compatibility, integrability, time), based on implementation theories. Results Stakeholders provided a wide range of RMM proposals, some beyond the regulatory remit. Patients and most HCPs converged remarkably, but there was some divergence among HCPs on the informed choice objective, the therapeutic place of valproate, the RMM appropriateness, and RMM delivery to HCPs and patients. Ethical aspects emerged as relevant for regulatory decision making, and crucial input gaps were identified from an RMM implementation perspective. Nine pilotable proposals for PRAC were made regarding: (A) Agreeing on appropriate RMM with stakeholders and catalysing healthcare leadership for implementation; (B) Building-up stakeholder input on all elements critical to RMM implementation guided by the ASSET; and (C) Collaborating with all stakeholders for monitoring implementation and evaluating RMM. Conclusions New implementation theory-based approaches are promising for enhancing the valuable dialogue between regulators, patients and HCPs and achieving patient safety. EU PAS Register number: EUPAS35947

Suggested Citation

  • Priya Bahri & Daniel R. Morales & Adrien Inoubli & Jean-Michel Dogné & Sabine M. J. M. Straus, 2021. "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Enga," Drug Safety, Springer, vol. 44(2), pages 193-209, February.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:2:d:10.1007_s40264-020-01005-3
    DOI: 10.1007/s40264-020-01005-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-020-01005-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-020-01005-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:2:d:10.1007_s40264-020-01005-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.